Nonergot Dopamine Agonist global drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic Ltd	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET;ORAL	090429-004	Mar 24, 2010	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mlv	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET;ORAL	079165-001	Feb 7, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Accord Hlthcare	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET;ORAL	204022-003	Feb 28, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Prinston Inc	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204413-004	May 11, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Nonergot dopamine agonists are led commercially by ropinirole (IR/ER), pramipexole (IR/ER), and rotigotine (transdermal patch). The patent landscape is dominated by (1) composition-of-matter filings from the late 1980s to early 2000s, (2) line extensions for extended-release (ER), alternative salts/particle forms, and dosing regimens, and (3) device or delivery system claims for rotigotine patches. Most jurisdictions are now in a mixed post-primary era where formulation and method-of-use patents control risk for specific dosage forms, not the whole molecule.

Because your scope is a class-level market and IP view, the actionable picture is: near-term brand revenue is concentrated in ER and patch products where secondary patents can still delay generic entry, while core “nonergot dopamine agonist” molecule patents are mostly expired. The residual legal exposure is therefore concentrated in FDA ANDA timing, Orange Book “listed” patents, and litigation over design-around of ER technologies and transdermal delivery.

Which nonergot dopamine agonists drive the market and how are they segmented?

What drugs are included in the nonergot dopamine agonist category

The class is typically built around dopamine receptor agonism without ergot-derived chemistry. The dominant small-molecule products are:

Ropinirole: Parkinson’s disease (PD), including immediate-release (IR) and extended-release (ER) formulations.
Pramipexole: PD, including IR and ER formulations.
Rotigotine: PD and, in many markets, restless legs syndrome (RLS) via transdermal patch.

Commercially relevant “brand pillars” (by molecule and dose form) are generally:

Ropinirole ER vs IR
Pramipexole ER vs IR
Rotigotine patch vs oral dopamine agonists

How do prescriber behavior and product form shift demand

Market dynamics in nonergot dopamine agonists typically hinge on:

Tolerability and dosing frequency (ER reduces peak/trough effects and dosing burden).
Adherence (patch can improve adherence versus oral dosing, especially in RLS).
Reimbursement (ER and patch products face substitution pressure, but access policies often lag molecule-level generic availability).

Key competitive vectors that determine share

Formulation differentiation: ER technologies and transdermal delivery drive both clinical positioning and patent leverage.
Safety monitoring: orthostatic hypotension, hallucinations, impulse control disorders influence physician selection and can affect switching behavior between formulations.
Switching cost: chronic PD dosing makes payers and providers reluctant to switch early if a brand remains “locked” behind formulation patents and adverse-event profiles.

What patents protect nonergot dopamine agonists (ropinirole, pramipexole, rotigotine)?

How patent estates typically break down by claim type

Nonergot dopamine agonists usually have three overlapping layers:

Composition-of-matter
Defines the molecule and common salts or stereochemical definitions. These often expire first and shape early generic entry.
Formulation and delivery system patents
- Ropinirole ER: controlled-release matrix, coatings, osmotic or polymer-controlled systems.
- Pramipexole ER: controlled release mechanism and tablet architecture.
- Rotigotine patch: adhesive layer design, permeation control, reservoir structure, and manufacturing method.
Method-of-use patents
- Specific dosing schedules, titration regimens, or indication-specific uses.
- These can matter when Orange Book lists patents tied to labeled indications and prevent “at-risk” entry for a particular claim set.

Which jurisdictions matter for exclusivity and enforcement

For market execution and litigation risk, the decisive forums are:

US: Orange Book listings, Paragraph IV ANDA triggers, Hatch-Waxman litigation.
EU/UK: national SPC and marketing authorization data protection frameworks.
Canada and key emerging markets: often follow similar market-entry mechanisms but with different enforcement timelines.

When does ropinirole lose exclusivity and what are generic entry risks?

What matters for ropinirole-specific exclusivity

For ropinirole, the generic risk is generally formulation-specific:

If IR and ER have distinct Orange Book listed patents, ANDAs that match IR labeling may clear earlier than ER-focused filings.
If a listed patent covers the ER mechanism or specific dosage form, entry can be blocked or delayed by:
- §505(b)(2) or §505(j) litigation outcomes
- settlement agreements controlling launch dates
- “design-around” work that changes polymer/coating or release mechanics

How to think about Paragraph IV timing for ER products

Generic challengers often target:

“listed” formulation patents for ER,
or method-of-use patents tied to PD indication and labeled titration schedules.

A key market point is that ER tends to maintain premium pricing even after IR generic availability, so the highest stakes challenges are typically for ER.

Likely litigation and settlement pattern in ropinirole

In mature molecules, the pattern often looks like:

Early ANDA filings
Patent litigation on a subset of listed patents
Settlements that give the first generic a delayed launch window in exchange for dismissal

This creates “staggered entry” where:

IR generics launch first,
ER remains brand-dominant until the last meaningful ER formulation patent falls.

When does pramipexole lose exclusivity and what are biosimilar or ANDA risks?

Why pramipexole is different from biologics

Pramipexole is a small molecule. So biosimilar dynamics do not apply. The risk is ANDA-based entry against listed Orange Book patents.

What determines pramipexole generic entry

As with ropinirole, the main barriers are:

ER formulation patents (release system, tablet design)
method-of-use patents (label-specific dosing)
any salt/form patents if they are tied to the commercial product configuration

How do ER patents affect market structure

Pramipexole ER usually supports sustained brand value because:

switching to IR can be less convenient,
payer policies may prefer ER for persistence and adherence.

Once ER patents expire or are successfully designed around, pricing pressure accelerates and share typically shifts quickly to first-wave generics.

When does rotigotine lose exclusivity and how does transdermal delivery change the patent landscape?

What is patent-critical for rotigotine patches

Rotigotine’s transdermal system adds a larger IP surface:

permeation enhancers and adhesive layer composition
patch multilayer design and release rate control
manufacturing methods for uniform drug loading and stable delivery

As a result, even when the molecule-level patent ends, patch-specific patents can extend competitive differentiation.

What generic challengers typically attack for patch products

For transdermal dopamine agonists, ANDA or 505(j) routes depend on:

formulation equivalence and release characteristics,
compliance with patch structural specifications,
and Orange Book patent lists that may include delivery-system claims.

Is “generic patch” risk higher than oral ER?

Often yes, because delivery systems can be more complex to match and can have more litigable components. In practice, litigation can focus on whether a generic patch “avoids” the claimed multilayer architecture or manufacturing steps.

What is the Orange Book status of nonergot dopamine agonists?

How Orange Book status translates into real-world market timing

For each marketed nonergot dopamine agonist product, the Orange Book can include patents for:

active ingredient (composition-of-matter)
formulation/dosage form
method of use (linked to labeled indications)
sometimes medical device or delivery system aspects

Orange Book listings drive:

eligibility for “at risk” ANDA
the identity of patents asserted in Paragraph IV litigation
settlement design that controls launch timing

How to use Orange Book data in competitive planning

In practice, teams map:

the specific marketed strength/dosage form (IR vs ER vs patch),
each listed patent’s expiration date and regulatory exclusivity assumptions,
and whether the patent is likely to be asserted or already resolved in prior litigations.

How many patents typically cover nonergot dopamine agonists and what is their strength profile?

Patent count and density: the practical pattern

While the exact count varies by molecule and product configuration, nonergot dopamine agonist estates frequently show:

multiple continuation or diversification patents in formulation families,
separate claim sets for different controlled-release layers,
method-of-use continuations that can produce staggered listed expirations.

Strength drivers in these estates

Patent strength is usually highest where:

independent claims cover core formulation architecture,
and there is no close prior art gap undermining novelty.

Weakness emerges when:

the estate relies on narrow dependent claims or incremental design-around differences.
the listed patents are vulnerable due to prior-art overlap or obviousness arguments.

What patent litigation affects generic entry for ropinirole, pramipexole, and rotigotine?

Common litigation focal points

Across the class, asserted themes include:

infringement of ER controlled-release mechanism claims
infringement of patch delivery system claims
whether generic design-around avoids the key claim limitations
enforceability challenges (inequitable conduct, written description, obviousness)

What settlement agreements usually look like

Settlements for these mature products tend to:

define a launch date tied to the end of a specific listed patent expiration,
permit earlier entry for products that do not infringe other unasserted claims,
establish non-admission terms and dismissal with specific triggers.

How to interpret “first filer” behavior

First Paragraph IV filers usually litigate the most commercially valuable dosage forms:

ER over IR
patch over oral where patch has highest brand value

Launch sequencing across dosage forms then becomes the main determinant of revenue impact.

What FDA regulatory status matters for nonergot dopamine agonists (ANDAs, 505(b)(2), exclusivity)?

How the regulatory pathway affects IP risk

ANDAs (505(j)) generally certify to Orange Book patents and can trigger Paragraph IV litigation.
505(b)(2) can use literature or bridging studies and may still require patent carve-outs, depending on exclusivity and listed patents.

What regulators do not decide

Patent infringement is not adjudicated by FDA. FDA’s role is:

approving bioequivalence and formulation sameness standards,
listing patents in the Orange Book based on NDA sponsor submissions,
and granting tentative approvals contingent on litigation outcomes.

How does ropinirole compare with pramipexole for patent barriers and generic timing?

Key comparative economics

Ropinirole ER and pramipexole ER usually hold premium pricing compared with IR.
The more differentiated the release system, the higher the design-around burden for ANDA applicants.
Where Orange Book lists more formulation patents for ER, launch timing tends to be delayed.

Patent estate behavior

Ropinirole estates often feature multiple controlled-release families tied to ER.
Pramipexole estates similarly feature ER-focused layers and sometimes distinct method-of-use.

The main investment-grade takeaway is structural: both molecules show “formulation-first” generic risk, not molecule-level risk.

How does rotigotine compare with oral dopamine agonists in IP complexity?

Transdermal delivery expands patent surface

Compared to oral ER, rotigotine’s patch system generates:

more multilayer component claims,
more manufacturing method claims,
and more opportunities for infringement disputes over patch structure.

Competitive outcome

Generic patch launches typically occur later than oral equivalents after brand-level dominance because proving and litigating patch equivalence to a claimed delivery system takes longer.

Revenue exposure: where brand money is concentrated under the patent map

What dosage forms carry the biggest post-expiration risk

For this class, brand revenue exposure usually concentrates in:

ER products for ropinirole and pramipexole,
patch products for rotigotine,
and any strength ranges where the Orange Book lists the last meaningful patents.

What happens after the last listed patent falls

Once the final asserted formulation patent expires (or is invalidated/avoided by successful design-around), the market typically shifts rapidly due to:

price compression,
interchangeability substitution,
and payer formulary updates.

Key Takeaways

The nonergot dopamine agonist market is led by ropinirole, pramipexole, and rotigotine, with value concentrated in ER and patch dosage forms.
The patent landscape is mostly post-primary: molecule patents are largely out of the critical zone, while formulation and delivery system patents govern the remaining generic threat.
Orange Book listings drive the practical timing of ANDA challenges; the main litigation targets are ER and patch technology claims.
Rotigotine patch generally carries higher IP complexity than oral ER due to multilayer delivery system claims and manufacturing method coverage.

FAQs

1) What patent types delay generic entry for nonergot dopamine agonists after molecule expiration?
Formulation/delivery system patents for ER and transdermal patches and any label-linked method-of-use patents listed in the Orange Book.

2) Do biosimilars apply to nonergot dopamine agonists?
No. These are small molecules. Competitive risk is via ANDAs (and related Paragraph IV patent litigation).

3) What is the main difference in generic risk between ER tablets and IR tablets?
ER products typically have more litigable formulation mechanics, so Orange Book barriers can persist after IR entry.

4) Why do rotigotine generics face additional hurdles compared with oral generics?
Transdermal delivery creates more claim scope around patch multilayer structures, adhesives, permeation control, and manufacturing methods.

5) How do settlement agreements influence launch dates in this class?
Settlements commonly define brand-protected “switch-off” dates for specific dosage forms tied to expiration of key listed patents or resolved claim sets.

References

No sources were provided in the prompt, and this response does not include inline citations.